17-43051089-T-C
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 2P and 3B. PM1BP4_ModerateBP6
The NM_007294.4(BRCA1):āc.5306A>Gā(p.Tyr1769Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000465 in 1,613,850 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_007294.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000460 AC: 7AN: 152030Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000597 AC: 15AN: 251354Hom.: 0 AF XY: 0.0000957 AC XY: 13AN XY: 135880
GnomAD4 exome AF: 0.0000465 AC: 68AN: 1461820Hom.: 1 Cov.: 31 AF XY: 0.0000688 AC XY: 50AN XY: 727216
GnomAD4 genome AF: 0.0000460 AC: 7AN: 152030Hom.: 0 Cov.: 31 AF XY: 0.0000673 AC XY: 5AN XY: 74254
ClinVar
Submissions by phenotype
not provided Uncertain:3Benign:1
- -
Observed in individuals with breast and/or ovarian cancer, but also in unaffected controls (PMID: 21965345, 22752604, 25186627, 30287823, 29470806, 31907386); In silico analysis supports that this missense variant does not alter protein structure/function; Also known as 5425A>G; This variant is associated with the following publications: (PMID: 24728327, 21965345, 24362935, 22752604, 30209399, 30287823, 29470806, 30725392, 31907386, 34063308, 32803532, 25186627, 32812259, 25348405, 34981296) -
- -
- -
Breast-ovarian cancer, familial, susceptibility to, 1 Uncertain:2Benign:1Other:1
The missense variant c.5306A>G (p.Tyr1769Cys) in BRCA1 gene has been reported in individuals affected with breast and/or ovarian cancer, as wells as in healthy control individuals(Juwle A et.al.,2012). This variant has been reported to the ClinVar database as Uncertain Significance. The p.Tyr1769Cys variant is novel (not in any individuals) in 1000 Genomes and allele frequency of 0.00005968% is reported in gnomAD. The amino acid Tyr at position 1769 is changed to a Cys changing protein sequence and it might alter its composition and physico-chemical properties. The amino acid change p.Tyr1769Cys in BRCA1 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Uncertain Significance. -
- -
- -
- -
Hereditary breast ovarian cancer syndrome Uncertain:1Benign:1
- -
- -
Hereditary cancer-predisposing syndrome Benign:2
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
not specified Benign:1Other:1
- -
Variant summary: BRCA1 c.5306A>G (p.Tyr1769Cys) results in a non-conservative amino acid change located in the BRCT domain(IPR001357) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4.8e-05 in 1615312 control chromosomes, predominantly at a frequency of 0.00079 within the South Asian subpopulation in the gnomAD database, including 1 homozygote. This frequency is somewhat lower than estimated for a pathogenic variant in BRCA1 causing Hereditary Breast And Ovarian Cancer Syndrome (0.00079 vs 0.001). c.5306A>G has been reported in the literature in individuals affected with breast and/or ovarian cancer (e.g. Akbari_2011, Juwle_2012, So_2019, Kim_2020), however, it was also found in healthy controls (e.g. Juwle_2012, Bodian_2014). Co-occurrences with other pathogenic variants have been reported in the literature (BRCA2 c.2983G>T, p.Gly995X; Kim_2020) and in an internal sample (BRCA2 c.3455T>G, p.Leu1152X), providing supporting evidence for a benign role. At least two publications report experimental evidence evaluating an impact on protein function, with one classifying the effect of this variant on homology directed repair (HDR) as intermmediate (Finday_2018), and the other reporting that the variant resulted in 82% HDR activity versus WT BRCA1 (Guo_2023). The following publications have been ascertained in the context of this evaluation (PMID: 21965345, 24728327, 30209399, 37731132, 34981296, 22752604, 31907386, 34063308, 32812259, 30725392). ClinVar contains an entry for this variant (Variation ID: 55513). Based on the evidence outlined above, the variant was classified as likely benign. -
Breast and/or ovarian cancer Uncertain:1
- -
Malignant tumor of breast Benign:1
The p.Tyr1769Cys variant was identified in 1 of 2690 proband chromosomes (frequency: 0.0004) from individuals or families with hereditary breast and ovarian cancer and was present in 1 of 1362 control chromosomes (frequency: 0.001) from healthy individuals (Akbari 2011, Bodian 2014). The low number of observations of this variant is not substantive enough to draw a conclusion about clinical signifcance. The variant was not identified in GeneInsight, HGMD, UMD, COSMIC, BIC, Google or LOVD database searches. The variant was identified in the ClinVar database 2X with the clinical significance not provided. The p.Tyr1769 residue is not conserved in mammals and the variant amino acid Cysteine (Cys) is present in the mouse and chicken increasing the likelihood that this variant does not have clinical significance. Four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein, although this information is not very predictive of pathogenicity. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time, althouch we lean towards a more benign role for this variant. This variant is classified as predicted benign. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at